CervoMed (CRVO) Stock Price, News & Analysis

Company Overview

CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research programs are aimed at addressing conditions involving cognitive impairment and other neurological dysfunction.

CervoMed’s lead investigational product is neflamapimod, an orally administered, selective inhibitor of the p38 alpha enzyme. The company is evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurodegenerative disorder associated with cognitive, behavioral and movement-related symptoms. The compound has also been studied in other forms of dementia, including Alzheimer’s disease.

The company was formed through the combination of EIP Pharma and Diffusion Pharmaceuticals and adopted the CervoMed name in 2023. Its development activities are primarily centered on clinical research and trials in the United States. CervoMed does not currently market an approved commercial product.

Key Stats

• Today's Range: $3.17 to $3.34
• 50-Day Range: $2.41 to $3.34
• 52-Week Range: $2.13 to $10.00
• Volume: 231,609 shs
• Average Volume: 237,545 shs
• Market Capitalization: $48.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

CervoMed Stock Analysis - MarketRank™

CervoMed scored higher than 43% of companies evaluated by MarketBeat, and ranked 638th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CervoMed has a consensus price target of $21.00, representing about 552.2% upside from its current price of $3.22.

Amount of Analyst Coverage

CervoMed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CervoMed are expected to grow in the coming year, from ($2.38) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CervoMed is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CervoMed is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CervoMed has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.80% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 7.05.

Change versus previous month

Short interest in CervoMed has recently increased by 9.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CervoMed does not currently pay a dividend.

Dividend Growth

CervoMed does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for CervoMed this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for CRVO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

4 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CervoMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.80% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

25.15% of the stock of CervoMed is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRVO
• Previous Symbol: NASDAQ:CRVO
• CIK: 1053691
• Web: www.cervomed.com
• Phone: (617) 744-4400
• Fax: 434-220-0722
• Employees: 15
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CervoMed: $21.00
• High Price Target: $31.00
• Low Price Target: $7.00
• Potential Upside/Downside: +552.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: N/A
• Pretax Margin: -9,141.57%
• Return on Equity: -156.02%
• Return on Assets: -128.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.57
• Quick Ratio: 8.57

Sales & Book Value

• Annual Sales: $4.01 million
• Price / Sales: 12.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.97 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 15,120,000
• Free Float: 9,706,000
• Market Cap: $48.69 million
• Optionable: Not Optionable
• Beta: -0.75